[38] V. Jäger, K. Büssow, and T. Schirrmann, “Transient Recombinant Protein

Expression in Mammalian Cells,” in Animal Cell Culture, vol. 9, M. Al-Rubeai, Ed.

Basel: Springer, Cham, 2015, pp. 27–64.

[39] Y. Genzel, “Designing cell lines for viral vaccine production: Where do we stand?”

Biotechnol. J., vol. 10, no. 5, pp. 728–740, May 2015.

[40] E. Puente-Massaguer, M. Lecina, and F. Gòdia, “Application of advanced quanti-

fication techniques in nanoparticle-based vaccine development with the Sf9 cell

baculovirus expression system,” Vaccine, vol. 38, no. 7, pp. 1849–1859, Feb. 2020,

doi: 10.1016/j.vaccine.2019.11.087

[41] E. Puente-Massaguer, M. Lecina, and F. Gòdia, “Integrating nanoparticle quanti-

fication and statistical design of experiments for efficient HIV-1 virus-like particle

production in High Five cells,” Appl. Microbiol. Biotechnol., vol. 104, no. 4,

pp. 1569–1582, Feb. 2020, doi: 10.1007/s00253-019-10319-x

[42] F. Strobl, S. M. Ghorbanpour, D. Palmberger, and G. Striedner, “Evaluation of

screening platforms for virus-like particle production with the baculovirus expres-

sion vector system in insect cells,” Sci. Rep., vol. 10, no. 1, pp. 1–9, 2020, doi: 10.

1038/s41598-020-57761-w

[43] S. Gutiérrez-Granados, L. Cervera, A. A. Kamen, and F. Gòdia, “Advancements in

mammalian cell transient gene expression (TGE) technology for accelerated pro-

duction of biologics,” Crit. Rev. Biotechnol., pp. 1–23, Jan. 2018, doi: 10.1080/073

88551.2017.1419459

[44] N. Bono, F. Ponti, D. Mantovani, and G. Candiani, “Non-viral in vitro gene de-

livery: It is now time to set the bar!,” Pharmaceutics, vol. 12, no. 2, pp. 1–23, Feb.

2020, doi: 10.3390/pharmaceutics12020183

[45] L. R. Castilho, Â. M. Moraes, E. F. P. Augusto, and M. Butler, Animal Cell

Technology: From Biopharmaceuticals to Gene Therapy. New York: Taylor &

Francis, 2008.

[46] L. Cervera, S. Gutiérrez-Granados, M. Martínez, J. Blanco, F. Gòdia, and M. M.

Segura, “Generation of HIV-1 Gag VLPs by transient transfection of HEK 293

suspension cell cultures using an optimized animal-derived component free medium,”

J. Biotechnol., vol. 166, no. 4, pp. 152–165, 2013, doi: 10.1016/j.jbiotec.2013.05.001

[47] P. Steppert et al., “Purification of HIV-1 gag virus-like particles and separation of

other extracellular particles,” J. Chromatogr. A, vol. 1455, pp. 93–101, 2016, doi:

10.1016/j.chroma.2016.05.053

[48] S. Gutiérrez-Granados, L. Cervera, M. M. Segura, J. Wölfel, and F. Gòdia,

“Optimized production of HIV-1 virus-like particles by transient transfection in

CAP-T cells,” Appl. Microbiol. Biotechnol., vol. 100, no. 9, 3935–3947, 2016, doi:

10.1007/s00253-015-7213-x

[49] X. Shen, P. O. Michel, Q. Xie, D. L. Hacker, and F. M. Wurm, “Transient trans-

fection of insect Sf-9 cells in TubeSpin® bioreactor 50 tubes,” BMC Proc., vol. 5,

no. Suppl 8, p. P37, 2011, doi: 10.1186/1753-6561-5-s8-p37

[50] J. Vidigal et al., “RMCE-based insect cell platform to produce membrane proteins

captured on HIV-1 Gag virus-like particles,” Appl. Microbiol. Biotechnol., vol. 102,

no. 2, pp. 655–666, Jan. 2018.

[51] M. Tagliamonte, M. L. Visciano, M. L. Tornesello, A. De Stradis, F. M.

Buonaguro, and L. Buonaguro, “Constitutive expression of HIV-VLPs in stably

transfected insect cell line for efficient delivery system,” Vaccine, vol. 28, no. 39,

pp. 6417–6424, Sep. 2010.

[52] E. Puente-Massaguer, M. Lecina, and F. Gòdia, “Nanoscale characterization cou-

pled to multi-parametric optimization of Hi5 cell transient gene expression,” Appl.

Microbiol. Biotechnol., vol. 102, no. 24, pp. 10495–10510, Dec. 2018, doi: 10.1

007/s00253-018-9423-5

262

Bioprocessing of Viral Vaccines